Abstract:Abstract Abstract 592 Arsenicals represent one group of the oldest drugs used in both traditional Chinese medicine (TCM) and Western medicine since 2,000 years ago to treat a variety of ailments from periodic fever to cancer. Recently, this ancient remedy has been revived due to its remarkable therapeutic efficacy for acute promyelocytic leukemia (APL) through selective degradation of the leukemogenic PML-RARaƒn as well as the wild-type PML protein. However, the precise molecular mechanism leading to arsenic-initiated modulationƒn of the target proteins remained unclear. Here we show that arsenic directly binds to PML and PML-RARaƒn through their RBCC (RING-B box-coiled coil) domain which contains conserved cysteine/histidine residues with metal-binding ability. Among RBCC domain, the RING and B2 motif are responsible for arsenic binding in cells, with recombinant RING motif showing the highest affinity to arsenic binding in vitro. We also observed that arsenic tends to coordinate with three sulfur atoms from the three conserved cysteines in the RING zinc finger. Arsenic binding alters the native structure of RING coordinated with zinc and induces its oligomerization through arsenic-mediated conformational change by intramolecular coordination as well as cross-linking between two RING motifs. Following conformational change and oligomerization of PML RBCC with arsenic binding, PML and PML-RARa undergoes SUMOylation through enhanced interaction with Ubc9, the E2 ligase for SUMOylation. Our findings provide the evidence that the PML RBCC domain is the direct target of arsenic and that the structural change of PML RBCC induced by arsenic binding facilitates the enhanced interaction with the cellular enzymatic machinery for protein SUMOylation/ubiquitination, which ultimately leads to the degradation of PML-RARa and cell differentiation and/or apoptosis. This mechanism sheds new insights into the mechanism of action of As2O3 for APL treatment, a model of targeted cancer therapy. Disclosures: No relevant conflicts of interest to declare.

Reinvent Aliphatic Arsenicals as Reversible Covalent Warheads toward Targeted Kinase Inhibition and Non-acute Promyelocytic Leukemia Cancer Treatment

Comparative Proteome Study of Apoptosis Induced by As4S4 in Retinoid Acid Resistant Human Acute Promyelocytic Leukemia NB4-R1 Cells

1,3-Benzodioxole Derivatives Improve the Anti-Tumor Efficiency of Arsenicals

Arsenic Binding To Rbcc Domain Modulates Oncogenic Pml-Rara And Wild-Type Pml As A Key Molecular Mechanism Of Arsenic Trioxide Treatment For Apl

Arsenene: A Potential Therapeutic Agent for Acute Promyelocytic Leukaemia Cells by Acting on Nuclear Proteins

Arsenic induced epigenetic changes and relevance to treatment of acute promyelocytic leukemia and beyond

Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib.

Carbonyl reductase 1 offers a novel therapeutic target to enhance leukemia treatment by arsenic trioxide

Rationally designed BCR-ABL kinase inhibitors for improved leukemia treatment via covalent and pro-/dual-drug targeting strategies

AcGlcAs: A Novel P53-Targeting Arsenical with Potent Cellular Uptake and Cancer Cell Selectivity.

Identification of Highly Efficacious PROTACs Targeting BRD4 Against Acute Myeloid Leukemia: Design, Synthesis, and Biological Evaluations

Acute Promyelocytic Leukemia, Retinoic Acid, and Arsenic: A Tale of Dualities

The novel thioredoxin reductase inhibitor A-Z2 triggers intrinsic apoptosis and shows efficacy in the treatment of acute myeloid leukemia

Combining Retinoic Acid and Oral Arsenic May Be Potentially the First-Line Therapy for Non-High-risk Acute Promyelocytic Leukemia.

Targeting Metabolic Dependencies in Acute Myeloid Leukemia: A Dual Strategy using Arsenic Trioxide and Artesunate.

When Poisons Cure: The Case of Arsenic in Acute Promyelocytic Leukemia

Efficacy and resistance of molecularly targeted therapy for myeloid malignancies Mechanisms of action and resistance to all-trans retinoic acid ( ATRA ) and arsenic trioxide ( As 2 O 3 ) in acute promyelocytic leukemia

Tetra-Arsenic Tetra-Sulfide For The Treatment Of Acute Promyelocytic Leukemia: A Pilot Report

Therapeutic Strategy of Arsenic Trioxide in the Fight Against Cancers and Other Diseases

Arsenic compounds: The wide application and mechanisms applied in acute promyelocytic leukemia and carcinogenic toxicology

Arsenene Nanodots with Selective Killing Effects and their Low‐Dose Combination with ß‐Elemene for Cancer Therapy